Drug intelligence / Profile preview

MV-NIS + atezolizumab

Development stage: Unknown
Lead developer: Vyriad
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral, Intravenous

Overview

MV-NIS + atezolizumab is a combination therapy consisting of an attenuated measles virus genetically engineered to produce sodium iodide symporter (MV-NIS) and atezolizumab, a PD-L1 inhibitor. This combination is being investigated for the treatment of recurrent and metastatic non-small cell lung cancer (NSCLC). MV-NIS is administered intratumorally, while atezolizumab is given intravenously. The therapy aims to leverage both oncolytic viral therapy and immune checkpoint inhibition to enhance anti-tumor responses.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on MV-NIS + atezolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MV-NIS + atezolizumab.

Explore the full profile